Abstract | PURPOSE: METHODS: HF was produced in 12 dogs by intracoronary microembolizations. Dogs were randomized to 3 months oral therapy with eplerenone (10 mg/kg twice daily, n = 6) or to no therapy at all (HF-control, n = 6). LV tissue from six normal dogs was used for comparison. mRNA expression was measured using reverse-transcriptase polymerase chain reaction (RT-PCR) and protein expression using Western blots. RESULTS: CONCLUSIONS:
|
Authors | Sharad Rastogi, Sudhish Mishra, Valerio Zacà, Issa Alesh, Ramesh C Gupta, Sidney Goldstein, Hani N Sabbah |
Journal | Cardiovascular drugs and therapy
(Cardiovasc Drugs Ther)
Vol. 21
Issue 6
Pg. 415-22
(Dec 2007)
ISSN: 0920-3206 [Print] United States |
PMID | 17940859
(Publication Type: Journal Article, Research Support, N.I.H., Extramural)
|
Chemical References |
- Angiotensin-Converting Enzyme Inhibitors
- Cytoskeletal Proteins
- Mineralocorticoid Receptor Antagonists
- RNA, Messenger
- Tissue Inhibitor of Metalloproteinase-1
- Tissue Inhibitor of Metalloproteinase-2
- Spironolactone
- Eplerenone
- Matrix Metalloproteinases
|
Topics |
- Angiotensin-Converting Enzyme Inhibitors
(therapeutic use)
- Animals
- Cytoskeletal Proteins
(genetics)
- Dogs
- Eplerenone
- Heart Failure
(drug therapy, metabolism)
- Matrix Metalloproteinases
(genetics)
- Mineralocorticoid Receptor Antagonists
(pharmacology)
- RNA, Messenger
(analysis)
- Spironolactone
(analogs & derivatives, pharmacology)
- Tissue Inhibitor of Metalloproteinase-1
(genetics)
- Tissue Inhibitor of Metalloproteinase-2
(genetics)
|